ResearcherMackay Memorial HospitalActive in the last 2 years
Pei‐Ming Yang
Matched on ORCID iD 0000-0002-4004-2518; OpenAlex author ID A5034407820. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper
Papers 8
- Fedratinib induces non-classical G2/M arrest via mitotic-kinase inhibition and synergizes with mitomycin C to suppress pancreatic ductal adenocarcinoma. First author DOI 10.1158/1535-7163.mct-26-0137↗
- A machine learning framework using urinary biomarkers for pancreatic ductal adenocarcinoma prediction with post hoc validation via single-cell transcriptomics. Co-author DOI 10.1093/bib/bbaf583↗
- Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma based on data mining and experimental anal… First author DOI 10.1186/s12967-025-06292-x↗
- Dasatinib inhibits PD-L1 expression via a proteasomal pathway in pancreatic ductal adenocarcinoma cells. Last author DOI 10.7150/jca.124262↗
- Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.3390/ijms23126559↗
- CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. Last author DOI 10.3390/jcm9124019↗
- Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirst… Last author DOI 10.3390/jpm10030130↗
- Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocar… Last author DOI 10.3390/genes10100766↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ching‐Chung Ko · 3 shared papers, 2022–2025 · strength 1.22
- Paper Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma ba… DOI 10.1186/s12967-025-06292-x↗
- Paper Dasatinib inhibits PD-L1 expression via a proteasomal pathway in pancreatic ductal adenocarcinoma cells. DOI 10.7150/jca.124262↗
- Paper Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Panc… DOI 10.3390/ijms23126559↗
- Hui-Ying Li · 1 shared paper, 2026 · strength 0.63
- Yao‐Yu Hsieh · 3 shared papers, 2019–2022 · strength 0.56
- Paper Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Panc… DOI 10.3390/ijms23126559↗
- Paper Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Ade… DOI 10.3390/jpm10030130↗
- Paper Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in … DOI 10.3390/genes10100766↗
- Ngoc Uyen Nhi Nguyen · 1 shared paper, 2025 · strength 0.22
- Dahlak Daniel Solomon · 1 shared paper, 2025 · strength 0.22
- Jiunn-Chang Lin · 1 shared paper, 2020 · strength 0.19
- Li-Wei Liu · 1 shared paper, 2020 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.